Molecular adjuvants for mucosal immunity.
Mucosal surfaces represent the entry route of a multitude of viral pathogens. For many of these viruses, such as the herpes simplex viruses and human immunodeficiency virus, no effective vaccine exists. Hence, it is important that prospective vaccines engender maximal immunity at these susceptible sites. Genetic vaccines encoding adjuvant molecules represent one approach to optimize mucosal as well as systemic immunity. Promising candidates include various inflammatory cytokines and chemokines that might be used to enhance the primary response to a level sufficient for protection. Encouraging studies involving cytokines such as granulocyte/macrophage colony-stimulating factor, interleukin-2 (IL-2), IL-12, IL-18, and many others are examined. Notable chemokines that may offer hope in such efforts include IL-8, RANTES, CCL19, CCL21, and a few others. Combinatorial approaches utilizing several cytokines and chemokines will most likely yield the greatest success. In addition, as more is discovered regarding the requirements for memory development of T cells, boosters involving key cytokines such as IL-15 and IL-23 may prove beneficial to long-term maintenance of the memory pool. This review summarizes the progress in the use of genetic vaccines to achieve mucosal immunity and discusses the needed strategies to maximize long-term prospective immunity at this vulnerable entry site.
Toka
Felix N
FN
Department of Microbiology, University of Tennessee, Walter's Life Sciences Building, Knoxville, TN 37996, USA.
Pack
Christopher D
CD
Rouse
Barry T
BT
D000276:Adjuvants, Immunologic / Q000235:genetics*; D016207:Cytokines / Q000235:genetics*; D006801:Humans; D018928:Immunity, Mucosal; D009092:Mucous Membrane / Q000276:immunology; D019444:Vaccines, DNA / Q000235:genetics* / Q000276:immunology*
D000276:Adjuvants, Immunologic; D016207:Cytokines; D019444:Vaccines, DNA